The relationship between circulating visfatin/nicotinamide phosphoribosyltransferase, obesity, inflammation and lipids profile in elderly population, determined by structural equation modeling

References

• Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994;14:1431–7.
   PubMed Web of Science ®Google Scholar
• Wang T, Zhang X, Bheda P, Revollo JR, Imai S, Wolberger C. Structure of Nampt/PBEF/visfatin, a mammalian NAD + biosynthetic enzyme. Nat Struct Mol Biol 2006;13:661–2.
   PubMed Web of Science ®Google Scholar
• Revollo JR, Körner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, Sasaki Y, Wolberger C, Townsend RR, Milbrandt J, Kiess W, Imai S. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007;6:363–75.
   PubMed Web of Science ®Google Scholar
• Yang H, Yang T, Baur JA, Perez E, Matsui T, Carmona JJ, Lamming DW, Souza-Pinto NC, Bohr VA, Rosenzweig A, de Cabo R, Sauve AA, Sinclair DA. Nutrient-sensitive mitochondrial NAD + levels dictate cell survival. Cell 2007;130:1095–7.
   PubMed Web of Science ®Google Scholar
• Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748–58.
   PubMed Web of Science ®Google Scholar
• Olszanecka-Glinianowicz M, Kocełak P, Janowska J, Skorupa A, Nylec M, Zahorska-Markiewicz B. Plasma visfatin and tumor necrosis factor-alpha (TNF-α) levels in metabolic syndrome. Kardiol Pol 2011;69:802–7.
   PubMed Web of Science ®Google Scholar
• Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 2011;27:515–27.
   PubMed Web of Science ®Google Scholar
• Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005;54:2911–16.
   PubMed Web of Science ®Google Scholar
• Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, Kocełak P, Semik-Grabarczyk E, Holecki M, Holecki M, Dabrowski P, Skorupa A. Serum concentration of visfatin in obese women. Metab Clin Exp 2007;56:1131–4.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Derdemezis CS, Kiortsis DN, Tselepis AD, Elisaf MS. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest 2007;30:323–16.
   PubMed Web of Science ®Google Scholar
• Unlütürk U, Harmanci A, Yildiz BO, Bayraktar M. Dynamics of Nampt/visfatin and high molecular weight adiponectin in response to oral glucose load in obese and lean women. Clin Endocrinol (Oxf) 2010;72:469–74.
   PubMed Web of Science ®Google Scholar
• Jaleel A, Aheed B, Jaleel S, Majeed R, Zuberi A, Khan S, Ahmed B, Shoukat F, Hashim H. Association of adipokines with obesity in children and adolescents. Biomark Med 2013;7:731–5.
   PubMed Web of Science ®Google Scholar
• Sandeep S, Velmurugan K, Deepa R, Mohan V. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metab Clin Exp 2007;56:565–70.
   PubMed Web of Science ®Google Scholar
• Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, Milan G, Rossato M, Federspil G, Vettor R. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006;91:3165–70.
   PubMed Web of Science ®Google Scholar
• de Luis DA, Ballesteros M, Ruiz E, Muñoz C, Penacho A, Iglesias P. Grupo de Nutrición, Sociedad Castellano Leonesa de Endocrinología, diabetes y nutrición. [Visfatin in obese patients, relation with cardiovascular risk factors, a cross sectional study]. Med Clin (Barc) 2011;137:199–203.
   PubMed Web of Science ®Google Scholar
• de Luis DA, Sagrado MG, Aller R, Conde R, Izaola O. Circulating visfatin in obese non-diabetic patients in relation to cardiovascular risk factors, insulin resistance, and adipocytokines: a contradictory piece of the puzzle. Nutrition 2010;26:1130–1.
   PubMed Web of Science ®Google Scholar
• Chang YC, Chang TJ, Lee WJ, Chuang LM. The relationship of visfatin/pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids. Metabolism 2010;59:93–9.
   PubMed Web of Science ®Google Scholar
• Körner A, Garten A, Blüher M, Tauscher R, Kratzsch J, Kiess W. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007;92:4783–91.
   PubMed Web of Science ®Google Scholar
• Kocełak P, Olszanecka-Glinianowicz M, Owczarek A, Krupa W, Obirek P, Bożentowicz-Wikarek M, Brzozowska A, Mossakowska M, Zdrojewski T, Skalska A, Więcek A, Chudek J. Plasma visfatin/nicotinamide phosphoribosyltransferase (visfatin/NAMPT) concentration in elderly subjects with metabolic syndrome. Pol Arch Med Wewn 2015;125:402–13.
   PubMed Web of Science ®Google Scholar
• Varma V, Yao-Borengasser A, Rasouli N, Bodles AM, Phanavanh B, Lee MJ, Starks T, Kern LM, Spencer HJ 3rd, McGehee RE Jr, Fried SK, Kern PA. Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J Clin Endocrinol Metab 2007;92:666–72.
   PubMed Web of Science ®Google Scholar
• Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006;49:1909–14.
   PubMed Web of Science ®Google Scholar
• Olszanecka-Glinianowicz M, Kocełak P, Nylec M, Chudek J, Zahorska-Markiewicz B. Circulating visfatin level and visfatin/insulin ratio in obese women with metabolic syndrome. Arch Med Sci 2012;8:214–18.
   PubMed Web of Science ®Google Scholar
• López-Bermejo A, Chico-Julià B, Fernàndez-Balsells M, Recasens M, Esteve E, Casamitjana R, Casamitjana R, Ricart W, Fernández-Real JM. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006;55:2871–5.
   PubMed Web of Science ®Google Scholar
• Ciardi C, Tatarczyk T, Tschoner A, Kranebitter M, Niederwanger A, Ebenbichler CF, Patsch JR, Pedrini MT. Effect of postprandial lipemia on plasma concentrations of A-FABP, RBP-4 and visfatin. Nutr Metab Cardiovasc Dis 2010;20:662–8.
   PubMed Web of Science ®Google Scholar
• Mabrouk R, Ghareeb H, Shehab A, Omar K, El-Kabarity RH, Soliman DA, Mohamad NA. Serum visfatin, resistin and IL-18 in A group of Egyptian obese diabetic and non-diabetic individuals. Egypt J Immunol 2013;20:1–11.
   PubMedGoogle Scholar
• Esteghamati A, Morteza A, Zandieh A, Jafari S, Rezaee M, Nakhjavani M, Jamali A, Esteghamati AR, Khalilzadeh O. The value of visfatin in the prediction of metabolic syndrome: a multi-factorial analysis. J Cardiovasc Transl Res 2012;5:541–6.
   PubMed Web of Science ®Google Scholar
• Miazgowski T, Safranow K, Krzyżanowska-Świniarska B, Iskierska K, Widecka K. Adiponectin, visfatin and regional fat depots in normal weight obese premenopausal women. Eur J Clin Invest 2013;43:783–90.
   PubMed Web of Science ®Google Scholar
• Güdücü N, İsçi H, Görmüş U, Yiğiter AB, Dünder İ. Serum visfatin levels do not increase in post-menopausal women with metabolic syndrome. J Endocrinol Invest 2013;36:57–61.
   Web of Science ®Google Scholar
• Laudes M, Oberhauser F, Schulte DM, Freude S, Bilkovski R, Mauer J, Rappl G, Abken H, Hahn M, Schulz O, Krone W. Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans. Horm Metab Res 2010;42:268–73.
   PubMed Web of Science ®Google Scholar
• Friebe D, Neef M, Kratzsch J, Erbs S, Dittrich K, Garten A, Petzold-Quinque S, Blüher S, Reinehr T, Stumvoll M, Blüher M, Kiess W, Körner A. Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia 2011;54:1200–11.
   PubMed Web of Science ®Google Scholar
• Lu YC, Hsu CC, Yu TH, Wang CP, Lu LF, Hung WC, Chiu CA, Chung FM, Lee YJ, Tsai IT. Association between visfatin levels and coronary artery disease in patients with chronic kidney disease. Iran J Kidney Dis 2013;7:446–52.
   PubMed Web of Science ®Google Scholar
• Chen CC, Li TC, Li CI, Liu CS, Lin WY, Wu MT, Lai MM, Lin CC. The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women. Metab Clin Exp 2007;56:1216–20.
   PubMed Web of Science ®Google Scholar
• Miazgowski T, Major-Gołuch A, Safranow K. Selected adipokines and metabolic profiles in normal-weight women with abdominal obesity. Pol Arch Med Wewn 2012;122:406–12.
   PubMed Web of Science ®Google Scholar
• Wang P, van Greevenbroek MM, Bouwman FG, Brouwers MC, van der Kallen CJ, Smit E, Keijer J, Mariman EC. The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile. Pflugers Arch 2007;454:971–86.
   PubMed Web of Science ®Google Scholar
• Olszanecka-Glinianowicz M, Owczarek A, Bożentowicz-Wikarek M, Brzozowska A, Mossakowska M, Zdrojewski T, Grodzicki T, Wiecek A, Chudek J. Relationship between circulating visfatin/NAMPT, nutritional status and insulin resistance in an elderly population – results from the PolSenior substudy. Metabolism 2014;63:1409–18.
   PubMed Web of Science ®Google Scholar
• Kocelak P, Olszanecka-Glinianowicz M, Owczarek A, Bozentowicz-Wikarek M, Brzozowska A, Mossakowska M, Zdrojewski T, Grodzicki T, Więcek A, Chudek J. Plasma visfatin/nicotinamide phosphoribosyltransferase levels in hypertensive elderly: results from the PolSenior substudy. J Am Soc Hypertens 2015;9:1–9.
   PubMed Web of Science ®Google Scholar
• Stevenson JE, Wright BR, Boydstun AS. The metabolic syndrome and coronary artery disease: a structural equation modeling approach suggestive of a common underlying pathophysiology. Metabolism 2012;61:1582–8.
   PubMed Web of Science ®Google Scholar
• Błedowski P, Mossakowska M, Chudek J, Grodzicki T, Milewicz A, Szybalska A, Wieczorowska-Tobis K, Wiecek A, Bartoszek A, Dabrowski A, Zdrojewski T. Medical, psychological, social, and economic aspects of aging in Poland (PolSenior): research assumptions and objectives. Exp Gerontol 2011;46:1003–9.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Technical report series 894: Obesity: Preventing and managing the global epidemic. Geneva: WHO, 2000.
   Google Scholar
• Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469–80.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013;36:S11–66.
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1990; 30:461–70.
   Google Scholar
• Grubbs FE. Procedures for detecting outlying observations in samples. Technometrics 1996;11:1–21.
   Google Scholar
• Billor N, Hadi AS, Velleman PF. BACON: blocked adaptive computationally efficient outlier nominators. Comput Stat Data Anal 2000;34:279–98.
   Web of Science ®Google Scholar
• Schreiber JB. Core reporting practices in structural equation modeling. Res Social Adm Pharm 2008;4:83–97.
   PubMed Web of Science ®Google Scholar
• Violato C, Hecker KG. How to use structural equation modeling in medical education research: a brief guide. Teach Learn Med 2007;19:362–71.
   PubMed Web of Science ®Google Scholar
• Hox JJ, Bechger TM. An introduction to structural equation modeling. Fam Sci Rev 1998;11:354–73.
   Google Scholar
• Hooper D, Coughlan J, Mullen MR. Structural equation modelling: guidelines for determining model fit. Electr J Business Res Met 2008;6:53–60.
   Web of Science ®Google Scholar
• Shen BJ, Todaro JF, Niaura R, McCaffery JM, Zhang J, Spiro A, Ward KD. Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. Am J Epidemiol 2003;157:701–11.
   PubMed Web of Science ®Google Scholar
• Terra X, Auguet T, Quesada I, Aguilar C, Luna AM, Hernández M, Sabench F, Porras JA, Martínez S, Lucas A, Pellitero S, Llutart J, del Castillo D, Richart C. Increased levels and adipose tissue expression of visfatin in morbidly obese women: the relationship with pro-inflammatory cytokines. Clin Endocrinol (Oxf) 2012;77:691–8.
   PubMed Web of Science ®Google Scholar
• Lajunen TK, Purhonen AK, Haapea M, Ruokonen A, Puukka K, Hartikainen AL, Savolainen MJ, Morin-Papunen L, Tapanainen JS, Franks S, Järvelin MR, Herzig KH. Full-length visfatin levels are associated with inflammation in women with polycystic ovary syndrome. Eur J Clin Invest 2012;42:321–8.
   PubMed Web of Science ®Google Scholar
• Sommer G, Kralisch S, Kloting N, Kamprad M, Schrock K, Kratzsch J, Tonjes A, Lossner U, Bluher M, Stumvoll M, Fasshauer M. Visfatin is a positive regulator of MCP-1 in human adipocytes in vitro and in mice in vivo. Obesity (Silver Spring) 2010;18:1486–92.
   PubMed Web of Science ®Google Scholar
• Permana PA, Menge C, Reaven PD. Macrophage-secreted factors induce adipocyte inflammation and insulin resistance. Biochem Biophys Res Commun 2006;341:507–14.
   PubMed Web of Science ®Google Scholar
• Höfer S, Benzer W, Alber H, Ruttmann E, Kopp M, Schüssler G, Doering S. Determinants of health-related quality of life in coronary artery disease patients: a prospective study generating a structural equation model. Psychosomatics 2005;46:212–23.
   PubMed Web of Science ®Google Scholar
• Waters KA, Mast BT, Vella S, de la Eva R, O’brien LM, Bailey S, Tam CS, Wong M, Baur LA. Structural equation modeling of sleep apnea, inflammation, and metabolic dysfunction in children. J Sleep Res 2007;16:388–95.
   PubMed Web of Science ®Google Scholar